Corium International, Inc. (NASDAQ:CORI) had its price target decreased by research analysts at Jefferies Group LLC to $8.00 in a note issued to investors on Wednesday. Jefferies Group LLC’s price objective suggests a potential upside of 173.97% from the stock’s previous close.
A number of other research firms have also weighed in on CORI. Zacks Investment Research lowered shares of Corium International from a “hold” rating to a “sell” rating in a report on Friday, November 25th. Cantor Fitzgerald initiated coverage on shares of Corium International in a report on Friday, December 16th. They set an “overweight” rating and a $10.00 target price on the stock. FBR & Co reissued a “buy” rating and issued a $18.00 price target on shares of Corium International in a research note on Tuesday, November 22nd. Leerink Swann set a $16.00 price target on shares of Corium International and gave the stock a “buy” rating in a research note on Tuesday, November 22nd. Finally, Needham & Company LLC cut their price target on shares of Corium International from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $10.21.
Corium International (NASDAQ:CORI) opened at 2.92 on Wednesday. Corium International has a 1-year low of $2.67 and a 1-year high of $8.33. The company’s market cap is $65.71 million. The stock’s 50 day moving average is $3.69 and its 200 day moving average is $4.84.
Corium International (NASDAQ:CORI) last posted its earnings results on Monday, February 13th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by $0.04. The firm had revenue of $7 million for the quarter, compared to the consensus estimate of $8.07 million. Corium International had a negative return on equity of 359.24% and a negative net margin of 116.26%. Equities analysts anticipate that Corium International will post ($1.67) earnings per share for the current fiscal year.
“Jefferies Group LLC Lowers Corium International, Inc. (CORI) Price Target to $8.00” was reported by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this piece of content can be read at https://baseballnewssource.com/markets/jefferies-group-llc-lowers-corium-international-inc-cori-price-target-to-8-00/434943.html.
A hedge fund recently raised its stake in Corium International stock. RTW Investments LLC raised its position in shares of Corium International, Inc. (NASDAQ:CORI) by 3.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 852,961 shares of the biopharmaceutical company’s stock after buying an additional 24,629 shares during the period. Corium International makes up 1.0% of RTW Investments LLC’s holdings, making the stock its 21st largest position. RTW Investments LLC owned 3.83% of Corium International worth $2,960,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 67.75% of the company’s stock.
Corium International Company Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with our FREE daily email newsletter.